Landmark cardiogenic shock trial criteria capture only a small, high-risk subset of the real-world population, revealing a substantial evidence gap for most patients receiving temporary MCS.
Current landmark trials for temporary mechanical circulatory support in cardiogenic shock lack generalizability to the broader real-world patient population, necessitating enhanced registry enrollment and innovative analytic strategies.
Patients meeting the landmark CS trial criteria represent a small, high-risk subset of the real-world CS population, highlighting a substantial evidence gap for the majority of CS patients receiving tMCS in clinical practice. Enhancing registry enrollment of specific CS subsets and adopting innovative analytic strategies could bridge gaps between randomized controlled trials findings and real-world applicability.
Li et al. (Tue,) conducted a review in Cardiogenic shock (CS). Temporary mechanical circulatory support (tMCS) was evaluated. Landmark cardiogenic shock trial criteria capture only a small, high-risk subset of the real-world population, revealing a substantial evidence gap for most patients receiving temporary MCS.